SCHEMBL5219967

SCHEMBL5219967

FC(F)(F)c1ccc2[nH]c(-c3csc(Nc4ncccc4Cl)n3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 6/20 0.47
▸ CBFB Q13951 2/20 0.44
▸ NPY5R Q15761 1/20 0.43
▸ VCP P55072 1/20 0.41
▸ ALOX5 P09917 2/20 0.39
▸ NPC1 O15118 4/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ DYRK1B Q9Y463 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ SLC2A1 P11166 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ AGTR1 P30556 1/20 0.38
▸ OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219975 0.92 CBFB (0.54) KITCBFBNPY5RVCPDYRK1A
SCHEMBL14422260 0.83 KIT (0.45) KITCBFBNPY5RVCPALOX5
SCHEMBL6191101 0.81 CBFB (0.47) KITCBFBNPC1KMT2ARAB9A
SCHEMBL5214652 0.80 KIT (0.52) KITCBFBVCP
SCHEMBL5213900 0.79 KIT (0.54) KITCBFBVCP
SCHEMBL14422259 0.78 MEN1 (0.50) KITCBFBNPY5RVCPNPC1
SCHEMBL5221543 0.75 CBFB (0.41) KITCBFBNPC1RAB9A
SCHEMBL5214660 0.72 KIT (0.53) KITCBFBDYRK1ADYRK1B
SCHEMBL179138 0.72 CBFB (0.80) CBFBNPC1KMT2ARAB9AKDM4E
SCHEMBL14422261 0.71 PLAU (0.44) KITALOX5NPC1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 — — US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 — — EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 — — EP disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KIT 266/4885CBFB 1560/4885NPY5R 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback